[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Izadi-Mood N, Samadi N, Sarmadi S, Eftekhar Z: Papillary serous carcinoma arising from adenomyosis presenting as intramural leiomyoma. Arch Iran Med; 2007 Apr;10(2):258-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary serous carcinoma arising from adenomyosis presenting as intramural leiomyoma.
  • Adenocarcinoma arising from adenomyosis uteri is rare.
  • Herein, we reported a patient with papillary serous carcinoma arising from adenomyosis.
  • The patient was a 61-year-old woman who received tamoxifen for treatment of her breast cancer over the past five years.
  • In one of these foci, papillary serous carcinoma was found.
  • [MeSH-major] Carcinoma, Papillary / pathology. Endometriosis / pathology. Leiomyoma / diagnosis. Myometrium / pathology. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Atrophy. Breast Neoplasms / drug therapy. Female. Humans. Middle Aged. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Adenomyosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367236.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


2. Maounis N, Chorti M, Legaki S, Ellina E, Emmanouilidou A, Demonakou M, Tsiafaki X: Metastasis to the breast from an adenocarcinoma of the lung with extensive micropapillary component: a case report and review of the literature. Diagn Pathol; 2010;5:82
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis to the breast from an adenocarcinoma of the lung with extensive micropapillary component: a case report and review of the literature.
  • Breast metastasis from extra-mammary malignancy is rare.
  • The primary malignancies most commonly metastasizing to the breast are leukemia-lymphoma, and malignant melanoma.
  • We present a case of metastasis to the breast from a pulmonary adenocarcinoma, with extensive micropapillary component, diagnosed concomitantly with the primary tumor.
  • Additionally, on physical examination a poorly defined mass was noted in the upper outer quadrant of the left breast.
  • The patient underwent bronchoscopy, excisional breast biopsy and medical thoracoscopy.
  • By cytology, histology and immunohistochemistry primary lung adenocarcinoma with metastasis to the breast and parietal pleura was diagnosed.
  • The patient received chemotherapy but passed away within 7 months.
  • Accurate differentiation of metastatic from primary carcinoma is of crucial importance because the treatment and prognosis differ significantly.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Carcinoma, Papillary / secondary. Lung Neoplasms / pathology. Pleural Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy. Bronchoscopy. Chemotherapy, Adjuvant. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Mammography. Predictive Value of Tests. Thoracoscopy. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Ultrasound Med. 2000 Apr;19(4):257-62 [10759349.001]
  • [Cites] J Surg Oncol. 2010 Feb 1;101(2):137-40 [20082359.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2259-66 [11745279.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):358-64 [11859208.001]
  • [Cites] Virchows Arch. 2002 Apr;440(4):353-61 [11956814.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1825-6 [12820464.001]
  • [Cites] Med Oncol. 2003;20(2):181-4 [12835522.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):137-41 [19875957.001]
  • [Cites] Mod Pathol. 2010 May;23(5):654-61 [20173733.001]
  • [Cites] Diagn Pathol. 2010;5:37 [20565809.001]
  • [Cites] Am Surg. 2004 Apr;70(4):287-90 [15098776.001]
  • [Cites] Adv Anat Pathol. 2004 Nov;11(6):297-303 [15505530.001]
  • [Cites] Cancer. 1972 Jun;29(6):1691-6 [4337956.001]
  • [Cites] AJR Am J Roentgenol. 1977 Oct;129(4):673-6 [409241.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 Jul;89(4):251-6 [7315321.001]
  • [Cites] Acta Oncol. 1992;31(4):479 [1632985.001]
  • [Cites] South Med J. 1997 Oct;90(10):1063-4 [9347825.001]
  • [Cites] Australas Radiol. 1998 Feb;42(1):16-9 [9509597.001]
  • [Cites] Acta Chir Belg. 2005 Feb;105(1):59-61 [15790204.001]
  • [Cites] APMIS. 2006 May;114(5):381-5 [16725015.001]
  • [Cites] Breast J. 2006 Jul-Aug;12(4):366-7 [16848849.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):103-13 [17145637.001]
  • [Cites] Australas Radiol. 2007 Apr;51(2):133-8 [17419856.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):731-7 [17582626.001]
  • [Cites] South Med J. 2007 Aug;100(8):850-1 [17715476.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1333-41 [18042689.001]
  • [Cites] Arch Pathol Lab Med. 2008 Feb;132(2):239-43 [18251583.001]
  • [Cites] Am J Surg Pathol. 2008 Mar;32(3):426-32 [18300807.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):682-7 [18048381.001]
  • [Cites] Pathology. 2008 Jun;40(4):345-51 [18446623.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2B):1299-301 [18505069.001]
  • [Cites] APMIS. 2009 Oct;117(10):762-7 [19775345.001]
  • [Cites] Gen Thorac Cardiovasc Surg. 2009 Oct;57(10):534-9 [19830516.001]
  • [Cites] Eur Radiol. 2001;11(9):1659-65 [11511887.001]
  • (PMID = 21167048.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] Adenocarcinoma of lung
  • [Other-IDs] NLM/ PMC3018363
  •  go-up   go-down


3. Jensen A, Sharif H, Svare EI, Frederiksen K, Kjaer SK: Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. Cancer Epidemiol Biomarkers Prev; 2007 Jul;16(7):1400-7
MedlinePlus Health Information. consumer health - Female Infertility.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study.
  • BACKGROUND: Few epidemiologic studies have examined the association between fertility drugs and breast cancer risk, and results have been contradicting.
  • Using data from the largest cohort of infertile women to date, the aim of this study was to examine the effects of fertility drugs on breast cancer risk overall and according to histologic subtypes.
  • A detailed data collection, including information of type and amount of treatment, was conducted.
  • We used case-cohort techniques to calculate rate ratios (RR) of breast cancer associated with use of five groups of fertility drugs, after adjustment for parity status.
  • RESULTS: Three hundred thirty-one invasive breast cancers were identified in the cohort during follow-up through 1998.
  • Analyses within cohort showed no overall increased breast cancer risk after use of gonadotrophins, clomiphene, human chorionic gonadotrophin, or gonadotrophin-releasing hormone, whereas use of progesterone increased breast cancer risk (RR, 3.36; 95% confidence interval, 1.3-8.6).
  • For all groups of fertility drugs, no relationships with number of cycles of use or years since first use of fertility drug were found.
  • However, gonadotrophins may have a stronger effect on breast cancer risk among nulliparous women (RR, 1.69; 95% confidence interval, 1.03-2.77).
  • CONCLUSION: The results showed no strong association between breast cancer risk and use of fertility drugs.
  • Follow-up is, however, needed to assess long-term breast cancer risk after use of progesterone and among nulliparous women exposed to gonadotrophins.
  • [MeSH-major] Breast Neoplasms / epidemiology. Fertility Agents, Female / administration & dosage. Infertility, Female / drug therapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / epidemiology. Adolescent. Adult. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / epidemiology. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / epidemiology. Case-Control Studies. Cohort Studies. Denmark / epidemiology. Female. Humans. Incidence. Middle Aged. Population Surveillance. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17585058.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fertility Agents, Female
  •  go-up   go-down


Advertisement
4. Kameda C, Tanaka H, Yamasaki A, Nakamura M, Koga K, Sato N, Kubo M, Kuroki S, Tanaka M, Katano M: The Hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer. Anticancer Res; 2009 Mar;29(3):871-9
Hazardous Substances Data Bank. CYCLOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer.
  • Understanding the expression patterns of estrogen receptor-alpha (ERalpha) is essential for determining therapeutic strategies for patients with breast cancer.
  • The prognosis of patients with ERalpha-negative breast cancer is still poor.
  • We have previously shown that Hedgehog (Hh) signaling is constitutively activated in breast cancer and that Hh signaling could be a new therapeutic target.
  • Therefore, in this study, whether or not Hh signaling could be utilized as a therapeutic target for patients with ERalpha-negative breast cancer was examined.
  • For this purpose, three ERalpha-negative breast cancer cell lines were used in which Hh pathway-related molecules such as the ligand Patched1 and the transcriptional factor Gli1 as target cells are expressed.
  • Since our previous data have shown a constitutive activation of the Hh pathway in surgically-resected ERalpha-negative breast cancer specimens, the Hh pathway, especially Gli1, may be a useful therapeutic target for patients with ERalpha-negative breast cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Carcinoma, Papillary / metabolism. Estrogen Receptor alpha / metabolism. Hedgehog Proteins / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Aged. Cell Proliferation / drug effects. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Invasiveness. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Tumor Cells, Cultured. Veratrum Alkaloids / pharmacology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414322.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Transcription Factors; 0 / Veratrum Alkaloids; 0 / estrogen receptor alpha, human; ZH658AJ192 / cyclopamine
  •  go-up   go-down


5. Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, Cohen P, Longo VD: Fasting and cancer treatment in humans: A case series report. Aging (Albany NY); 2009 Dec;1(12):988-1007
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fasting and cancer treatment in humans: A case series report.
  • Short-term fasting (48 hours) was shown to be effective in protecting normal cells and mice but not cancer cells against high dose chemotherapy, termed Differential Stress Resistance (DSR), but the feasibility and effect of fasting in cancer patients undergoing chemotherapy is unknown.
  • Here we describe 10 cases in which patients diagnosed with a variety of malignancies had voluntarily fasted prior to (48-140 hours) and/or following (5-56 hours) chemotherapy.
  • None of these patients, who received an average of 4 cycles of various chemotherapy drugs in combination with fasting, reported significant side effects caused by the fasting itself other than hunger and lightheadedness.
  • Chemotherapy associated toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI).
  • The six patients who underwent chemotherapy with or without fasting reported a reduction in fatigue, weakness, and gastrointestinal side effects while fasting.
  • In those patients whose cancer progression could be assessed, fasting did not prevent the chemotherapy-induced reduction of tumor volume or tumor markers.
  • Although the 10 cases presented here suggest that fasting in combination with chemotherapy is feasible, safe, and has the potential to ameliorate side effects caused by chemotherapies, they are not meant to establish practice guidelines for patients undergoing chemotherapy.
  • Only controlled-randomized clinical trials will determine the effect of fasting on clinical outcomes including quality of life and therapeutic index.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Fasting. Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Papillary / diet therapy. Cystadenocarcinoma, Serous / drug therapy. Esophageal Neoplasms / drug therapy. Female. Humans. Male. Middle Aged. Prostatic Neoplasms / drug therapy. Uterine Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Cell Cycle. 2002 Nov-Dec;1(6):375-82 [12548008.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6659-63 [15096581.001]
  • [Cites] J Pharmacol Exp Ther. 1980 Jun;213(3):551-6 [7193726.001]
  • [Cites] J Clin Invest. 1983 Feb;71(2):175-82 [6681614.001]
  • [Cites] J Nutr. 1986 Apr;116(4):641-54 [3958810.001]
  • [Cites] Cancer Res. 1988 Sep 1;48(17):4766-9 [2842038.001]
  • [Cites] Toxicol Lett. 1989 Mar;46(1-3):163-75 [2650023.001]
  • [Cites] Nutrition. 1989 May-Jun;5(3):155-71; discussion 172 [2520283.001]
  • [Cites] Endocr Rev. 1994 Feb;15(1):80-101 [8156941.001]
  • [Cites] Arch Dis Child. 1994 Nov;71(5):457-62 [7826122.001]
  • [Cites] Exp Gerontol. 1995 May-Aug;30(3-4):291-8 [7556508.001]
  • [Cites] Science. 2003 Feb 28;299(5611):1342-6 [12610293.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20915-24 [12665508.001]
  • [Cites] J Cell Biol. 1997 Jun 30;137(7):1581-8 [9199172.001]
  • [Cites] Mech Ageing Dev. 1998 Aug 14;104(2):149-58 [9792193.001]
  • [Cites] CA Cancer J Clin. 2006 Nov-Dec;56(6):323-53 [17135691.001]
  • [Cites] Free Radic Biol Med. 2007 Mar 1;42(5):665-74 [17291990.001]
  • [Cites] JAMA. 2007 Mar 7;297(9):986-94 [17341713.001]
  • [Cites] Annu Rev Nutr. 2007;27:193-217 [17428180.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8215-20 [18378900.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4535-6 [18626003.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Nov;9(11):903-10 [18946478.001]
  • [Cites] Science. 2009 Jul 10;325(5937):201-4 [19590001.001]
  • [Cites] Int J Obes Relat Metab Disord. 2001 Aug;25(8):1233-9 [11477509.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jun;87(6):2978-83 [12050283.001]
  • [Cites] Nature. 2003 Jan 9;421(6919):182-7 [12483226.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4301-5 [11389048.001]
  • (PMID = 20157582.001).
  • [ISSN] 1945-4589
  • [Journal-full-title] Aging
  • [ISO-abbreviation] Aging (Albany NY)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2815756
  • [Keywords] NOTNLM ; Cancer / Chemotherapy / IGF-I / Side-effect / Toxicity / fasting
  •  go-up   go-down


6. Tsunoda-Shimizu H, Hayashi N, Hamaoka T, Kawasaki T, Tsugawa K, Yagata H, Kikuchi M, Suzuki K, Nakamura S: Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging. Breast Cancer; 2008;15(2):133-40
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging.
  • BACKGROUND: Neoadjuvant chemotherapy has recently become common therapy for breast cancer.
  • This work studied whether or not the effects of neoadjuvant chemotherapy can be predicted from morphological features of breast cancer in initial diagnostic imaging.
  • MATERIALS AND METHODS: A total of 186 cases who underwent neoadjuvant chemotherapy at this hospital in 2006 were studied.
  • One is a type of invasive carcinoma that tends to grow along the mammary ducts (type A1), another is a type of expansively growing invasive carcinoma that is relatively well-defined (type A2), a third is a type of irregularly shaped mass that retracts surrounding tissue (type A3), and the fourth is a mixed type.
  • Thus, the effects of neoadjuvant chemotherapy on carcinomas of the four types were compared on the basis of image and pathological findings.
  • Effects of neoadjuvant chemotherapy were classified into three categories of enlarged mass, pCR, and other, with the latter indicating no change or shrinkage.
  • RESULTS: Of the 186 total cases, 72 were classified as type A1, 31 as type A2, 52 as type A3, and 31 as a mixed type.
  • Seven of 31 cases of type A2 (22.6%) were cases of an enlarged mass, revealing a high percentage of such cases.
  • Dividing cases into type A2 and other types and looking at the proportion of cases of an enlarged mass thus indicated a significantly higher tendency. pCR was achieved in 6 of 31 cases with type A2 (19.4%).
  • Here, also, the proportion of type A2 cases was significantly higher.
  • CONCLUSION: Morphological features prior to neoadjuvant chemotherapy can contribute to determining the effects of the therapy.
  • Expansively growing well-defined masses contain lesions at both extremes, tending to enlarge in some instances or instead allowing pCR, so the course of therapy must be carefully followed when performing neoadjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Neoadjuvant Therapy
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Ductal, Breast / classification. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / classification. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Carcinoma, Papillary / classification. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / pathology. Chemotherapy, Adjuvant. Cyclophosphamide / therapeutic use. Diagnostic Imaging. Epirubicin / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Middle Aged. Prognosis. Retrospective Studies. Stereoisomerism. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18288570.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; FEC protocol
  •  go-up   go-down


7. Kimura M, Tominaga T, Takatsuka Y, Toi M, Abe R, Koyama H, Takashima S, Nomura Y, Miura S, Kimijima I, Tashiro H, Ohashi Y, Adjuvant CEF Research Group for Breast Cancer: Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan. Breast Cancer; 2010 Jul;17(3):190-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
  • BACKGROUND: To compare the cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy and the anthracycline-containing regimen cyclophosphamide, epirubicin, and fluorouracil (CEF) to evaluate the efficacy and safety of the latter.
  • METHODS: A total of 294 patients with axillary node-positive primary breast cancer of STAGE I-IIIa were randomly assigned to either CEF [cyclophosphamide (CPA) 500 mg/m(2) i.v. days 1 and 8; epirubicin (EPI) 60 mg/m(2) i.v. day 1; and 5-fluorouracil (5-FU) 500 mg/m(2) i.v. days 1 and 8] or CMF [CPA 500 mg/m(2) i.v. days 1 and 8; methotrexate (MTX) 40 mg/m(2) i.v. days 1 and 8; and 5-FU 500 mg/m(2) i.v. days 1 and 8].
  • Both treatment regimens were comprised of six cycles at 4-week intervals.
  • Adverse drug reactions (ADRs) occurred more frequently in CEF.
  • The principal cause of the failure seems to be insufficient power, that is, the dose intensity (EPI: 60 mg/m(2)) set 10 years ago, when the trial began, was low, and the number of trial subjects was small because of the background of the times, which made the accumulation of cases extremely difficult.
  • However, the trial should be considered to be meaningful, as it was the first, formally conducted controlled trial on chemotherapy in Japan.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Papillary / drug therapy
  • [MeSH-minor] Adult. Axilla. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Japan. Lymphatic Metastasis. Methotrexate / administration & dosage. Middle Aged. Receptors, Estrogen / metabolism. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575284.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


8. Nio Y, Toga T, Maruyama R, Fukushima M: Expression of orotate phosphoribosyl transferase in human pancreatic cancer: implication for the efficacy of uracil and tegafur-based adjuvant chemotherapy. Oncol Rep; 2007 Jul;18(1):59-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of orotate phosphoribosyl transferase in human pancreatic cancer: implication for the efficacy of uracil and tegafur-based adjuvant chemotherapy.
  • The enzyme orotate phosphoribosyl transferase (OPRT) is involved in the metabolism of the anticancer drug 5-fluorouracil (5-FU), and is a key enzyme for conversion of 5-FU to its active form in tumor tissue.
  • The present study was designed to assess the association between the activity of OPRT in the tumor, and the clinicopathological status and prognosis of human resectable pancreatic cancer, especially regarding its relevance to the efficacy of adjuvant chemotherapy with uracil and tegafur (UFT), cyclophosphamide (CPA) and/or gemcitabine (GEM).
  • In the OPRT (+) group, the survival rate of the patients, who received adjuvant chemotherapy (ACT) with UFT, CPA or GEM, was significantly higher than that of the patients without ACT; however, in the OPRT (-) group, there was no difference in the survival between the ACT (+) and (-) groups.
  • The present study is the first report on the significance of OPRT in human pancreatic cancer, and the results indicate that the expression of OPRT may be useful to predict the response to adjuvant chemotherapy in human pancreatic cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / enzymology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Pancreatic Ductal / enzymology. Carcinoma, Papillary / enzymology. Orotate Phosphoribosyltransferase / metabolism. Pancreatic Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549346.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 1548R74NSZ / Tegafur; 8N3DW7272P / Cyclophosphamide; B76N6SBZ8R / gemcitabine; EC 2.4.2.10 / Orotate Phosphoribosyltransferase; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Varras M, Akrivis Ch, Bellou A, Malamou-Mitsi VD, Antoniou N, Tolis C, Salamalekis E: Primary fallopian tube adenocarcinoma: preoperative diagnosis, treatment and follow-up. Eur J Gynaecol Oncol; 2004;25(5):640-6
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube adenocarcinoma: preoperative diagnosis, treatment and follow-up.
  • Preoperative diagnosis of fallopian tube carcinoma is difficult due to the rarity and silent course of this neoplasm.
  • We present herein the case of a 58-year-old woman with primary fallopian tube carcinoma that was diagnosed preoperatively on the basis of a positive for adenocarcinoma Papanicolaou vaginal smear, repeated episodes of vaginal bleeding, negative endocervical and endometrial curettage, characteristic features on ultrasonography and elevated CA-125 levels.
  • Pathologic confirmation of primary serous papillary adenocarcinoma of the left fallopian tube was made.
  • FIGO stage was considered as IIIb and the patient received six courses of combined carboplatin-taxol chemotherapy.
  • At two years from onset of therapy the patient underwent a modified radical mastectomy and lymphadenectomy because of primary carcinoma of the right breast.
  • The patient was started on tamoxifen therapy, which she is still taking.
  • In conclusion, our study suggests an association between fallopian tube carcinoma and breast cancer and a good response of the patient to platinum-based chemotherapy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Cystadenocarcinoma, Papillary / diagnosis. Fallopian Tube Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Estrogen Antagonists / therapeutic use. Female. Humans. Mastectomy. Middle Aged. Neoplasm Staging. Postoperative Period. Preoperative Care. Tamoxifen / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15493187.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


10. Banneux N, Bonnet S: [Optic disc metastasis from pulmonary adenocarcinoma]. Bull Soc Belge Ophtalmol; 2007;(305):79-84
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Optic disc metastasis from pulmonary adenocarcinoma].
  • Metastases to the optic disc account only for 4.5% of all intraocular metastases and are most of the time accompanied by an adjacent juxtapapillary choroidal component.
  • The diagnosis of an optic disc metastasis was retained according to the ophthalmoscopy and various complementary investigations.
  • Breast and lung cancers are the most common primary neoplasms.
  • The mean age at the time of ocular diagnosis is 55 years.
  • The mean survival is 13 months after ocular diagnosis.
  • The mean treatments are external radiotherapy associated with systemic chemotherapy.
  • CONCLUSION: Presence of an optic disc lesion may suggest the possibility of a papillary metastasis despite the lack of a cancer history.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Lung Neoplasms / pathology. Optic Nerve Neoplasms / diagnosis. Optic Nerve Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018431.001).
  • [ISSN] 0081-0746
  • [Journal-full-title] Bulletin de la Société belge d'ophtalmologie
  • [ISO-abbreviation] Bull Soc Belge Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


11. Kitajima A, Amano S, Sakurai K, Enomoto K, Matsuo S, Negishi N, Oinuma T, Nemoto N: [A case of breast cancer detected by MRI mammography after Hollywood syndrome]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1786-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of breast cancer detected by MRI mammography after Hollywood syndrome].
  • A-64-year-old woman, who had been treated with augmentation mammaplasty 40 years ago, came to our hospital complaining of left breast pain.
  • The mass was ill-defined, located in the upper outer quadrant area of her breast, and was 2 cm in diameter.
  • The diagnosis was Class IV by the fine needle aspiration biopsy cytology.
  • We diagnosed the left breast cancer being in T2N0M0, Stage IIA, then we carried out Bt (Auchincloss method) and Sentinel lymph node biopsy (SLNB).
  • The histological diagnosis was papillotubular carcinoma, f+, n+ (8/11).
  • We dosed 6 cycles of FEC chemotherapy (CPA 800 mg, EPI 80 mg, 5-FU 750 mg/body x 1 cycle).
  • We recognized no side effects of the chemotherapy for the patient.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Implants. Breast Neoplasms / diagnosis. Carcinoma, Papillary / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Cyclophosphamide. Epirubicin. Female. Fluorouracil. Humans. Middle Aged. Sentinel Lymph Node Biopsy


12. Kurosumi M, Tabei T, Inoue K, Takei H, Ninomiya J, Naganuma R, Suemasu K, Higashi Y, Tsuchiya E: Prognostic significance of scoring system based on histological heterogeneity of invasive ductal carcinoma for node-negative breast cancer patients. Oncol Rep; 2003 Jul-Aug;10(4):833-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of scoring system based on histological heterogeneity of invasive ductal carcinoma for node-negative breast cancer patients.
  • This study aimed to determine the prognostic significance of histological scoring system based on heterogeneity of invasive ductal carcinoma, for node-negative breast cancer patients.
  • These results suggested that assessment of histological heterogeneity of invasive ductal carcinoma could serve as independent potent prognostic factor for node-negative invasive ductal carcinoma of the breast, and this method might be useful to decide indication of postoperative adjuvant chemotherapy.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Papillary / classification. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Scirrhous / classification. Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Adult. Aged. Female. Humans. Immunoenzyme Techniques. Lymph Nodes / metabolism. Middle Aged. Neoplasm Invasiveness. Prognosis. Receptors, Estrogen / metabolism. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12792731.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Estrogen
  •  go-up   go-down


13. Kilic-Okman T, Yardim T, Gücer F, Altaner S, Yuce MA: Breast cancer, ovarian gonadoblastoma and cervical cancer in a patient with Peutz-Jeghers Syndrome. Arch Gynecol Obstet; 2008 Jul;278(1):75-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer, ovarian gonadoblastoma and cervical cancer in a patient with Peutz-Jeghers Syndrome.
  • Patients with PJS have increased risk for gastrointestinal, breast, and female genital tract cancers.
  • In 2003, concomitant to cervical carcinoma, breast cancer was diagnosed.
  • Patient underwent left modified radical mastectomy due to the invasive papillary carcinoma.
  • The patient received six cycles combination chemotherapy and radiation therapy because of stage IIIB cervical cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Gonadoblastoma / diagnosis. Ovarian Neoplasms / diagnosis. Peutz-Jeghers Syndrome / complications. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Adult. Biomarkers, Tumor / blood. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / surgery. Fatal Outcome. Female. Humans. Mastectomy. Neoplasms, Multiple Primary


14. Enomoto K, Sakurai K, Amano S, Shiono M: [A case of advanced breast carcinoma with local hemorrhage during a control of hyperthyroidism]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2490-2
MedlinePlus Health Information. consumer health - Hyperthyroidism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced breast carcinoma with local hemorrhage during a control of hyperthyroidism].
  • Around the year 2006, the right breast lump was found by palpating.
  • A medical check-up was done and diagnosed as T4b, N0, M0, stage IIIB of the breast cancer by a close inspection.
  • In January 2009, we observed a bleeding from the part of the breast cancer.
  • Then we performed a pectoralis muscle preservation breast surgery and dermanaplasty with a shortest anesthesia time in order to control the infestation to be minimal.
  • Because we were able to control the hyperthyroidism this time and a thyroid function to be stabilized for a local advanced breast carcinoma with the hemorrhage temporarily, and were able to operate for the breast cancer, as we reported it in this study.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma, Ductal, Breast / complications. Hemorrhage / etiology. Hyperthyroidism / drug therapy
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / surgery. Carcinoma, Papillary / complications. Carcinoma, Papillary / surgery. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037465.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Enomoto K, Amano S, Sakurai K: [Two cases of obstructive jaundice that developed with breast cancer hepatic metastasis--a treatment by a bile duct stent obtaining high efficacy]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1907-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of obstructive jaundice that developed with breast cancer hepatic metastasis--a treatment by a bile duct stent obtaining high efficacy].
  • A Treatment by a Bile Duct Stent Obtaining High Efficacy: Katsuhisa Enomoto, Sadao Amano and Kenichi Sakurai (Division of Breast and Breast cancer hepatic metastasis with icterus is poor in prognosis and an active treatment is hardly performed.
  • However, we improved patients' QOL by inserting a bile duct stent as a topical treatment.
  • CASE 1: A 63-year-old woman was seen having left breast cancer.
  • Since then, we continued chemotherapy and hormonal therapy.
  • We detained a bile duct stent and performed a treatment to decrease the icterus.
  • CASE 2: A 49-year-old woman was seen having right breast cancer.
  • In conclusion, it appears that a bile duct stent has improved patients' QOL in the cases where obstructive jaundice developed with breast cancer hepatic metastasis.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Papillary / pathology. Jaundice, Obstructive / etiology. Jaundice, Obstructive / therapy. Liver Neoplasms / secondary. Stents

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212143.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


16. Dallenbach-Hellweg G, Schmidt D, Hellberg P, Bourne T, Kreuzwieser E, Dören M, Rydh W, Rudenstam G, Granberg S: The endometrium in breast cancer patients on tamoxifen. Arch Gynecol Obstet; 2000 Apr;263(4):170-7
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The endometrium in breast cancer patients on tamoxifen.
  • We restudied histologically and immunohistochemically 17 endometrial carcinomas, 2 malignant mixed tumors and 180 endometria with benign changes during or after tamoxifen therapy.
  • 20-33% had foci of mucinous, clear cell or serous-papillary metaplasia.
  • None of 11 patients biopsied before starting tamoxifen therapy had advanced endometrial glandular proliferation in the second endometrial biopsy after tamoxifen treatment.
  • None of the 19 endometrial neoplasms after tamoxifen therapy was of the endometrioid type: 11 were mucinous adenocarcinomas, 4 clear cell carcinomas, 2 serous-papillary carcinomas, one carcinosarcoma and one malignant Mullerian mixed tumor.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Endometrium / drug effects. Tamoxifen / adverse effects
  • [MeSH-minor] Adenocarcinoma, Clear Cell / chemically induced. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / ultrasonography. Adult. Aged. Aged, 80 and over. Biopsy. Carcinosarcoma / chemically induced. Carcinosarcoma / pathology. Carcinosarcoma / ultrasonography. Cystadenocarcinoma, Papillary / chemically induced. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / ultrasonography. Female. Humans. Immunohistochemistry. Middle Aged. Mixed Tumor, Mullerian / chemically induced. Mixed Tumor, Mullerian / pathology. Mixed Tumor, Mullerian / ultrasonography. Polyps. Retrospective Studies. Ultrasonography, Doppler, Color

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10834325.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


17. Hill KA, Rosen B, Shaw P, Causer PA, Warner E: Incidental MRI detection of BRCA1-related solitary peritoneal carcinoma during breast screening--A case report. Gynecol Oncol; 2007 Oct;107(1):136-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental MRI detection of BRCA1-related solitary peritoneal carcinoma during breast screening--A case report.
  • After four cycles of chemotherapy a localized, grade 3 serous papillary adenocarcinoma was resected followed by further chemotherapy and radiation.
  • She remains disease-free 3 years post-treatment.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Genes, BRCA1. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Breast Neoplasms / genetics. Fallopian Tubes / surgery. Female. Genetic Predisposition to Disease. Germ-Line Mutation. Humans. Incidental Findings. Magnetic Resonance Imaging. Middle Aged. Ovariectomy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629551.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Swerdlow AJ, Jones ME, British Tamoxifen Second Cancer Study Group: Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst; 2005 Mar 2;97(5):375-84
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
  • BACKGROUND: Tamoxifen treatment of breast cancer is associated with an increased risk of endometrial cancer, but tamoxifen-related risks of endometrial cancer are unclear in premenopausal women, in long-term users of tamoxifen, and in women for whom several years have passed since ending treatment.
  • METHODS: We compared treatment information on 813 case patients who had endometrial cancer after their diagnosis for breast cancer and 1067 control patients who had breast cancer but not subsequent endometrial cancer.
  • RESULTS: Overall, tamoxifen treatment, compared with no treatment, was associated with an increased risk of endometrial cancer (odds ratio [OR] = 2.4; 95% confidence interval [CI] = 1.8 to 3.0).
  • Risk increased statistically significantly (P(trend)<.001) with duration of treatment (for > or =5 years of treatment compared with no treatment, OR = 3.6, 95% CI = 2.6 to 4.8).
  • As an indication of background levels of treatment, 16% of control patients received 5 years or more of treatment.
  • Risk of endometrial cancer adjusted for treatment duration did not diminish in follow-up to at least 5 years after the last treatment ended.
  • Ever treatment with tamoxifen was associated with a much greater risk of Mullerian and mesodermal mixed endometrial tumors (OR = 13.5, 95% CI = 4.1 to 44.5) than of adenocarcinoma (OR = 2.1, 95% CI = 1.6 to 2.7) or clear cell and papillary serous tumors (OR = 3.1, 95% CI = 0.8 to 17.9).
  • CONCLUSIONS: There is an increasing risk of endometrial cancer associated with longer tamoxifen treatment, extending well beyond 5 years.
  • The increased risk of endometrial cancer associated with tamoxifen treatment should be considered clinically for both premenopausal and postmenopausal women during treatment and for at least 5 years after the last treatment.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Breast Neoplasms / prevention & control. Endometrial Neoplasms / chemically induced. Estrogen Receptor Modulators / adverse effects. Tamoxifen / adverse effects
  • [MeSH-minor] Aged. Case-Control Studies. England. Female. Humans. Logistic Models. Middle Aged. Mixed Tumor, Mesodermal / chemically induced. Mixed Tumor, Mullerian / chemically induced. Odds Ratio. Risk Assessment. Risk Factors. Selective Estrogen Receptor Modulators / adverse effects. Time Factors

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15741574.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Receptor Modulators; 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


19. Kolwijck E, Boss EA, van Altena AM, Beex LV, Massuger LF: Stage IV epithelial ovarian carcinoma in an 18 year old patient presenting with a Sister Mary Joseph's nodule and metastasis in both breasts: a case report and review of the literature. Gynecol Oncol; 2007 Dec;107(3):583-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: We describe an 18-year-old girl presenting with umbilical metastasis as a first sign of an extremely aggressive stage IV ovarian serous papillary adenocarcinoma without an objective response to chemotherapy and endocrine therapy.
  • She developed metastasis in both breasts and died 28 months after the initial diagnosis.
  • Furthermore, uncommon breast metastasis and a Sister Mary Joseph's nodule have never been described at such young age.
  • [MeSH-major] Breast Neoplasms / secondary. Ovarian Neoplasms / pathology. Umbilicus / pathology
  • [MeSH-minor] Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / secondary. Adolescent. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / secondary. Female. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17904207.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Cocco E, Casagrande F, Bellone S, Richter CE, Bellone M, Todeschini P, Holmberg JC, Fu HH, Montagna MK, Mor G, Schwartz PE, Arin-Silasi D, Azoudi M, Rutherford TJ, Abu-Khalaf M, Pecorelli S, Santin AD: Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC Cancer; 2010 Jul 02;10:349
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Development of innovative, effective therapies against recurrent/chemotherapy-resistant ovarian cancer remains a high priority.
  • METHODS: Because claudin-3 and -4 are the epithelial receptors for Clostridium perfringens enterotoxin (CPE), and are sufficient to mediate CPE binding, in this study we evaluated the in vitro and in vivo bioactivity of the carboxy-terminal fragment of CPE (i.e., CPE290-319 binding peptide) as a carrier for tumor imaging agents and intracellular delivery of therapeutic drugs.
  • Cell binding assays were used to assess the accuracy and specificity of the CPE peptide in vitro against primary chemotherapy-resistant ovarian carcinoma cell lines.
  • Confocal microscopy and biodistribution assays were performed to evaluate the localization and uptake of the FITC-conjugated CPE peptide in established tumor tissue.
  • RESULTS: Using a FITC-conjugated CPE peptide we show specific in vitro and in vivo binding to multiple primary chemotherapy resistant ovarian cancer cell lines.
  • Bio-distribution studies in SCID mice harboring clinically relevant animal models of chemotherapy resistant ovarian carcinoma showed higher uptake of the peptide in tumor cells than in normal organs.
  • Imunofluorescence was detectable within discrete accumulations (i.e., tumor spheroids) or even single chemotherapy resistant ovarian cancer cells floating in the ascites of xenografted animals while a time-dependent internalization of the FITC-conjugated CPE peptide was consistently noted in chemotherapy-resistant ovarian tumor cells by confocal microscopy.
  • CONCLUSIONS: Based on the high levels of claudin-3 and -4 expression in chemotherapy-resistant ovarian cancer and other highly aggressive human epithelial tumors including breast, prostate and pancreatic cancers, CPE peptide holds promise as a lead peptide for the development of new diagnostic tracers or alternative anticancer agents.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5007-11 [11016619.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6744-9 [11118061.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1176-81 [11158614.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3869-76 [11358798.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5895-904 [11479231.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):678-84 [11522752.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7878-81 [11691807.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):262-70 [11782386.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4722-9 [12183431.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):8-16 [12468336.001]
  • [Cites] Mol Carcinog. 2003 Feb;36(2):53-9 [12557260.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2567-75 [12855632.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):14-25 [15305371.001]
  • [Cites] Infect Immun. 1975 Aug;12(2):440-2 [168155.001]
  • [Cites] J Biol Chem. 1986 Feb 5;261(4):1801-7 [2418017.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):630-4 [7906395.001]
  • [Cites] Toxicon. 1996 Nov-Dec;34(11-12):1335-43 [9027990.001]
  • [Cites] J Cell Biol. 1997 Mar 24;136(6):1239-47 [9087440.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4334-42 [15899825.001]
  • [Cites] Virchows Arch. 2007 Sep;451(3):669-80 [17609977.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):7977-82 [17804705.001]
  • [Cites] Am J Obstet Gynecol. 2009 Jul;201(1):70.e1-9 [19426958.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • (PMID = 20598131.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-16359; United States / NCI NIH HHS / CA / R01 CA122728-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / Claudin-3; 0 / Claudin-4; 0 / Cldn3 protein, mouse; 0 / Cldn4 protein, mouse; 0 / Enterotoxins; 0 / Membrane Proteins; 0 / Peptide Fragments; 0 / RNA, Messenger; 0 / enterotoxin, Clostridium
  • [Other-IDs] NLM/ PMC2908101
  •  go-up   go-down


21. Bugat R, Bataillard A, Lesimple T, Voigt JJ, Culine S, Lortholary A, Merrouche Y, Ganem G, Kaminsky MC, Negrier S, Perol M, Laforêt C, Bedossa P, Bertrand G, Coindre JM, Fizazi K, FNCLCC, CRLCC: [Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site]. Bull Cancer; 2002 Oct;89(10):869-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Standards, Options et Recommandations 2002 pur la prise en charge des patients atteints de carcinomes de site primitif inconnu (rapport abrégé).
  • 1) An adapted immunochemistry test using a specific antibody battery should be performed for the anatomopathologic diagnosis.
  • 2) The aim of the diagnosis is to identify specific anatomoclinical forms that can be treated by a specific treatment (standard, level of evidence B2).
  • Except these forms, searching for the primary tumor site have no prognosis or therapeutic interest that can justify a systematic diagnosis assessment (standard, level of evidence B2).
  • 3) The management of poorly differentiated neuroendocrine carcinoma consists of platin/etoposide based chemotherapy.
  • There is no standard treatment for the differentiated forms.
  • 5) The management of axillary node metastases in women with adenocarcinoma should be the same as the management of patients with lymph node metastases in breast cancer.
  • If mammary MRI is negative, surgical treatment and mammary irradiation are not recommended and an axillary node excision should be performed.
  • 6) The standard treatment for women with primary papillary serous carcinoma of the peritoneum is a surgical resection followed by chemotherapy, as recommended for ovarian cancer.
  • 7) CUPS not belonging to any specific anatomoclinical forms can be treated by chemotherapy, symptomatic treatment alone or treatment based on biphosphonates in presence bone metastases.
  • [MeSH-major] Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / therapy
  • [MeSH-minor] Axilla. Carcinoma, Neuroendocrine / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Humans. Lymph Node Excision. Lymphatic Metastasis. Prognosis. Radiotherapy, Adjuvant. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12441278.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Guideline; Journal Article; Practice Guideline
  • [Publication-country] France
  •  go-up   go-down


22. Mili Boussen I, Kamoun R, Boussen H, Dhiab T, Rahal K, Hamzaoui A, Ouertani A: [Metastatic neoplasia in the optic nerve]. Rev Neurol (Paris); 2004 Nov;160(11):1071-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Papillary metastases have been exceptionally described, and represent only 5 percent of the ocular metastatic locations.
  • We report in this observation a case of papillary metastasis in a patient treated for a metastatic adenocarcinoma.
  • OBSERVATION: A 35-year-old woman was given chemotherapy for four months for metastatic adenocarcinoma involving the pleura and bones.
  • The fundus examination revealed a yellowish papillary lesion with edema associated with an inferior peripapillary serous retinal detachment.
  • The patient died four months after diagnosis of ocular metastasis and eleven months after diagnosis of adenocarcinoma.
  • CONCLUSION: Presence of a papillary lesion suggests the possible diagnosis of papillary metastasis despite the lack of a history of neoplasia.
  • Carcinomatosis tumors, especially breast and the lung carcinomas are the most frequent causes of papillary metastasis.
  • [MeSH-major] Adenocarcinoma / secondary. Neoplasms, Unknown Primary. Optic Nerve Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15602349.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Schmidt D, Horn LC: [Precancerous lesion of the endometrium and endometrial morphology in patients with tamoxifen therapy]. Zentralbl Gynakol; 2002 Jan;124(1):3-9
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Precancerous lesion of the endometrium and endometrial morphology in patients with tamoxifen therapy].
  • [Transliterated title] Präkanzeröse Läsionen des Endometriums und Veränderungen unter Tamoxifen-Therapie.
  • The endometrioid type of endometrial adenocarcinoma,(type 1-carcinoma) is estrogen-dependent and frequently associated with endometrial hyperplasia.
  • In postmenopausal patients treatment should consist of abdominal hysterectomy.
  • The so-called type 2-carcinomas, serous-papillary and clear-cell type, do not demonstrate a similar association with precursor lesions.
  • Patients with breast cancer and tamoxifen treatment have an increased risk of endometrial carcinoma.
  • In some of these patients it could be argued whether the carcinoma has developed in a proceeding endometrial hyperplasia.
  • [MeSH-minor] Endometrium / drug effects. Endometrium / pathology. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11873307.001).
  • [ISSN] 0044-4197
  • [Journal-full-title] Zentralblatt für Gynäkologie
  • [ISO-abbreviation] Zentralbl Gynakol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 38
  •  go-up   go-down


24. Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, Ng C, Wagner A, Hough G, Farias-Eisner G, Anantharamaiah GM, Van Lenten BJ, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R: Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A; 2010 Nov 16;107(46):19997-20002
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mice expressing a human apoA-I transgene had (i) increased survival (P < 0.0001) and (ii) decreased tumor development (P < 0.01), when compared with littermates, following injection of mouse ovarian epithelial papillary serous adenocarcinoma cells (ID-8 cells).

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Water .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2000 Apr;21(4):585-91 [10753190.001]
  • [Cites] Gynecol Oncol. 2008 Oct;111(1):102-5 [20698078.001]
  • [Cites] Circulation. 2002 Jan 22;105(3):290-2 [11804981.001]
  • [Cites] JAMA. 2002 Jun 19;287(23):3081-2 [12069669.001]
  • [Cites] Circulation. 2002 Aug 27;106(9):1127-32 [12196340.001]
  • [Cites] Vascul Pharmacol. 2002 Apr;38(4):211-8 [12449017.001]
  • [Cites] J Nutr Biochem. 2003 Feb;14(2):64-73 [12667597.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Sep 19;309(2):377-83 [12951060.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12343-8 [14523236.001]
  • [Cites] Circulation. 2004 Jun 29;109(25):3215-20 [15197147.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1185-91 [15247129.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Sep;24(9):1676-81 [15242861.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3884-8 [8033111.001]
  • [Cites] Biochem J. 1995 Aug 1;309 ( Pt 3):933-40 [7639713.001]
  • [Cites] Haematologica. 1996 Jul-Aug;81(4):343-45 [8870380.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):379-84 [9669823.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R640-6 [15535846.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Circ Res. 2005 Sep 16;97(6):524-32 [16100046.001]
  • [Cites] J Biol Chem. 2005 Nov 25;280(47):39485-92 [16179351.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4589-96 [16237736.001]
  • [Cites] Circ Res. 2005 Nov 25;97(11):1190-7 [16224061.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Jan;15(1):13-21 [16370930.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9643-8 [16769891.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25 [17179483.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):284-93 [17270017.001]
  • [Cites] Pancreas. 2007 Mar;34(2):205-14 [17312459.001]
  • [Cites] J Lipid Res. 2007 Nov;48(11):2344-53 [17693626.001]
  • [Cites] Methods Enzymol. 2007;433:1-25 [17954226.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jun;109(3):573-9 [17674197.001]
  • [Cites] J Lipid Res. 2008 Aug;49(8):1658-69 [18426778.001]
  • [Cites] Am J Obstet Gynecol. 2008 Sep;199(3):215-23 [18468571.001]
  • [Cites] J Lipid Res. 2008 Nov;49(11):2302-11 [18621920.001]
  • [Cites] Curr Opin Investig Drugs. 2008 Nov;9(11):1157-62 [18951294.001]
  • [Cites] Curr Atheroscler Rep. 2009 Jan;11(1):52-7 [19080728.001]
  • [Cites] Curr Atheroscler Rep. 2009 Jan;11(1):58-63 [19080729.001]
  • [Cites] Mol Cancer Ther. 2009 Jan;8(1):64-74 [19139114.001]
  • [Cites] J Lipid Res. 2009 Feb;50(2):204-13 [18812596.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):481-5 [19101714.001]
  • [Cites] Curr Opin Lipidol. 2009 Apr;20(2):157-8 [19276898.001]
  • [Cites] Neurobiol Dis. 2009 Jun;34(3):525-34 [19344763.001]
  • [Cites] Am J Obstet Gynecol. 2009 Jun;200(6):639.e1-5 [19285648.001]
  • [Cites] J Lipid Res. 2009 Jul;50(7):1293-304 [19224872.001]
  • [Cites] Mol Cancer Ther. 2009 Jun;8(6):1692-701 [19509252.001]
  • [Cites] J Biol Chem. 2009 Jul 3;284(27):18292-301 [19433579.001]
  • [Cites] J Lipid Res. 2009 Aug;50(8):1538-47 [19225094.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H866-73 [19561306.001]
  • [Cites] Kidney Int. 2009 Aug;76(4):437-44 [19471321.001]
  • [Cites] Kidney Int. 2009 Aug;76(4):359-61 [19644477.001]
  • [Cites] Cell Cycle. 2009 Oct 1;8(19):3191-8 [19755862.001]
  • [Cites] Gynecol Oncol. 2010 Jan;116(1):78-81 [19822357.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):164-8 [19608977.001]
  • [Cites] Cancer. 2010 Feb 1;116(3):544-73 [19998273.001]
  • [Cites] Antioxid Redox Signal. 2010 Apr 15;12(8):1009-59 [19686040.001]
  • [Cites] Anal Biochem. 2001 Mar15;290(2):302-13 [11237333.001]
  • (PMID = 21041624.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL030568; United States / NHLBI NIH HHS / HL / R01 HL082823; United States / NHLBI NIH HHS / HL / HL-082823; United States / NHLBI NIH HHS / HL / HL-30568
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoprotein A-I; 0 / Lysophospholipids; 0 / Peptides; 059QF0KO0R / Water; 22002-87-5 / lysophosphatidic acid
  • [Other-IDs] NLM/ PMC2993420
  •  go-up   go-down






Advertisement